The global bioimplant market was evaluated at $77,738 million in 2016, and is estimated to reach $124,154 million by 2023, with a CAGR of 6.9% during the forecast period. The growth in the bioimplant market is primarily attributed to the rise in prevalence of chronic diseases coupled with the rapidly aging population. Moreover, increased awareness and technological advancements in bioimplant further support the growth of the market. However, high implantation cost and lack of expertise are some of the factors that restrain the growth of the bioimplant market.
The global bioimplant market is segmented based on product type, material, and region. Based on product type, the market is categorized into cardiovascular implant, dental implant, orthopedic implant, spinal implant, ophthalmic implant, and others. By Material Type, it is divided into metallic biomaterial, ceramic biomaterial, polymer biomaterial, and natural biomaterials. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging trends and dynamics in the global bioimplants market to identify the prevailing opportunities.
It presents a competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- and country-wise analyses are provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Type
Cardiovascular bioimplant
Stent
Coronary stent
Drug-eluting stent (DES)
Bare-metal coronary stent
Bioabsorbable stent
Peripheral stent
Iliac
Femoral-popliteal
Renal
Carotid
Stent-related bioimplant
Synthetic graft
Vena Cava filter
Pacing device
Cardiac resynchronization therapy device (CRTs)
Implantable cardioverter defibrillator (ICDs)
Implantable cardiac pacemaker (ICPs)
Structural Cardiac Implant
Mechanical heart valve
Implantable ventricular-assist device
Dental bioimplant
Plate form dental implant
Root form dental implant
Orthopedic bioimplant
Reconstructive joint replacement
Knee replacement implant
Hip replacement implant
Extremities
Orthobiologics
Trauma & craniomaxillofacial
Spinal bioimplant
Spinal fusion implant
Spinal bone stimulator
Vertebral compression fracture (VCF) device
Motion preservation devices/non-fusion device
Spine biologics
Ophthalmology bioimplant
Glaucoma implant
Intraocular implant
Others
By material
Metallic biomaterial
Ceramic biomaterial
Polymers biomaterial
Natural biomaterial
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
The key players profiled in this report are as follows:
Abbott Laboratories (St. Jude Medical, Inc.)
Boston Scientific Corporation
Dentsply Sirona Inc.
Johnson & Johnson (Ethicon, Inc.)
Medtronic plc
Smith & Nephew plc
Stryker Corporation
Victrex Plc. (Invibio Ltd.)
Wright Medical Group N.V.
Zimmer Biomet Holdings Inc.
The other players in the value chain include (*These players have not been profiled in the report, but can be included on request.):
GC Aesthetics plc
Allergan Inc.
Sientra Inc.
Danaher Corporation
3M Company
Polytech Health & Aesthetics GmbH
B. Braun Melsungen AG
Elixir Medical Corporation
Microport Scientific Corporation
STENTYS S.A.
Terumo Corporation
Table of Contents
Executive Summary
According to a new report titled, "Bioimplants Market by Type, and Material: Global Opportunity Analysis and Industry Forecast, 2017-2023" the market was valued at $77,738 million in 2016, and is estimated to reach $124,154 million by 2023, with a CAGR of 6.9% during the forecast period.Bioimplant are devices of human or animal origin used to replace a missing natural body structure, support an injured biological part, or improve an existing biological structure. The major factors that contribute to the market growth include increase in geriatric population, rapid technological advancements, rise in incidence of chronic diseases, surge in adoption of advanced treatment devices, and growth in awareness regarding both the disease and treatment devices available in the market. However, the stringent approval procedure of the bioimplant is expected to impede the market growth. In addition, significant unmet need in the emerging nations provides a lucrative opportunity for the market.
The orthopedic bioimplant segment generated the maximum revenue, accounting for nearly 40% of the global digital bioimplant market in 2016. On the other hand, dental bioimplant segment is expected to witness the highest CAGR during the forecast period.
By material, the metallic biomaterial segment is expected to dominate the market, accounting for nearly two-thirds share in 2023. On the other hand, the polymeric biomaterials segment is estimated to register the highest CAGR during the forecast period.
Key findings of the Bioimplants Market:
The cardiovascular bioimplant segment contributed for nearly one-fourth share of the global bioimplant market in 2016.
The spinal bioimplant segment is projected to grow at a significant CAGR from 2017 to 2023.
The natural biomaterial segment is projected to grow at a significant CAGR during the forecast period.
Germany and France are the major shareholders, which collectively accounted for more than one-third share of the Europe bioimplant market in 2016.
Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific bioimplant market in 2016.
The North America market is projected to dominate the global bioimplant market in terms of revenue during the forecast period. This is majorly due to the increase in technological development and rise in incidence of cardiac, neuro, and spinal disorders. The Asia-Pacific market is expected to grow at the highest CAGR of 8.7% during the forecast period, owing to rise in awareness about the use of bio implants in the healthcare industry and surge in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.
The major companies profiled in the report are Abbott Laboratories (St. Jude Medical, Inc.), Boston Scientific Corporation, Dentsply Sirona Inc., Johnson & Johnson (Ethicon, Inc.), Medtronic Plc, Smith & Nephew Plc, Stryker Corporation, Victrex Plc. (Invibio Ltd.), Wright Medical Group N.V., and Zimmer Biomet Holdings Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...